Multiple sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
Intervention 1: Intervention group:The case group (30 MS patients) received sixty 500mg capsules of royal jelly prepared by Rodin Food Industry Company and they were asked to eat one capsule daily bef
Sponsors
Dezfoul University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of participants:: Patients' subtype of M.S should be the "relapsing-remitting MS" (RRMS). The patient's age should be 20- 45 years old and all of them treated with interferon for at least 6 months.
Exclusion criteria
Exclusion criteria: Patients with anemia, chronic heart disease, lung disease, diabetic Mellitus, autoimmune diseases such as rheumatoid arthritis, SLE, liver diseases, and a history of asthma and allergies. Patients are treated with corticosteroids or ACTH drugs, or consumption of supplements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expanded Disability Status Scale. Timepoint: Study of "Expanded Disability Status Scale" at the beginning of the study and on day 60 after the use of Royal Jelly. Method of measurement: Scoring from zero (best condition) to 10 (death due to MS) according to the neurologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of change in the amount of inflammatory cytokines. Timepoint: Investigating the level of inflammatory cytokines at the beginning of the study and on the 60th day after the end of using royal jelly. Method of measurement: Eliza method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahin Behzadifard
Dezfoul University of Medical Sciences
Outcome results
None listed